Table 3.
Quantitative RT-PCR results from purified patient samples
| TACC3 | FGFR3 | LETM1 | MMSET total | MMSET III | MMSET I | MMSET II | RE-IIBP | WHSC2 | |
|---|---|---|---|---|---|---|---|---|---|
| Patient no. | |||||||||
| 1335 | 1.34 | 0.56 | 8.36 | 4.66 | 10.08 | 11.13 | 3.24 | 11.39 | 11.06 |
| 1336 | 0.32 | 0.04 | 1.84 | 0.59 | 2.40 | 0.89 | 0.40 | 0.82 | 0.97 |
| 1677* | 0.33 | 0.04 | 1.54 | 1.04 | 2.17 | 2.49 | 0.90 | 0.93 | 0.95 |
| 1676* | 0.61 | 0.05 | 2.56 | 0.92 | 2.09 | 1.84 | 1.13 | 2.31 | 2.19 |
| 1668* | 0.19 | 0.01 | 1.19 | 0.61 | 0.96 | 0.94 | 0.68 | 0.29 | 1.03 |
| 1644* | 1.80 | 0.55 | 6.66 | 17.6 | 5.18 | 1.54 | 2.91 | 6.74 | 6.41 |
| 1645* | 5.37 | 8.25 | 5.69 | 1.82 | 2.76 | 0.81 | 1.40 | 3.47 | 4.51 |
| 1364 | 0.95 | 0.05 | 4.04 | 1.72 | 2.08 | 2.27 | 1.39 | 2.92 | 2.49 |
| 1243 | 0.55 | 0.05 | 3.53 | 1.14 | 2.83 | 0.71 | 0.85 | 1.53 | 2.72 |
| 527 | 1.03 | 0.01 | 1.20 | 0.71 | 1.63 | 0.68 | 0.55 | 0.53 | 1.30 |
| 1660* | 0.42 | 0.01 | 1.56 | 0.99 | 1.93 | 1.09 | 0.73 | 1.08 | 1.18 |
| 1504 [MB4-1, NEG] | 18.78 | 1.22 | 0.48 | 77.81 | 77.29 | 167.65 | 29.73 | 286.73 | 0.89 |
| 1560* [MB4-1, NEG] | 0.76 | 0.63 | 1.65 | 24.53 | 71.95 | 72.58 | 17.21 | 34.77 | 1.25 |
| 1649* [MB4-1, POS] | 0.74 | 339.10 | 4.49 | 22.13 | 95.90 | 14.02 | 22.84 | 140.61 | 2.97 |
| 1237 [MB4-1, POS] | 2.54 | 931.97 | 11.48 | 71.59 | 158.23 | 42.47 | 43.93 | 156.32 | 4.56 |
| 1308 [MB4-3, NEG] | 0.23 | 0.07 | 1.58 | 45.25 | 1.85 | 70.20 | 34.78 | 124.79 | 2.33 |
| 1661 [MB4-3, POS] | 0.21 | 58.10 | 0.90 | 12.47 | 0.65 | 27.86 | 9.60 | 24.48 | 0.79 |
| 1661 [MB4-3, POS] | 4.02 | 139.80 | 3.50 | 40.50 | 1.40 | 30.13 | 31.41 | 38.23 | 2.14 |
| Totals | |||||||||
| t(4;14)NEG mean | |||||||||
| REL (mean ΔCt) | 1.17 (8.63) | 0.87 (12.6) | 3.47 (4.91) | 2.89 (7.49) | 3.10 (10.4) | 2.22 (9.81) | 1.29 (4.78) | 2.91 (10.1) | 3.16 (5.67) |
| t(4;14)POS mean | |||||||||
| REL (mean ΔCt) | 3.90 (7.84) | 210 (4.90) | 3.44 (5.28) | 42.0 (2.91) | 58.2 (7.82) | 60.7 (4.84) | 27.1 (0.23) | 115 (4.48) | 2.13 (5.99) |
| ttest | .182 | .054 | .904 | < .001 | .005 | .001 | < .001 | .001 | .497 |
The relative expression level (REL) was determined by the ΔΔCt analysis method using the Raji cell line as a reference expression level of 1 for all reactions except FGFR3. Since Raji does not express FGFR3, we used the KMS-18 myeloma cell line as a reference expression level of 100, as this t(4;14)POS cell line had the highest expression level.
For t(4;14)POS samples, the breakpoint type and FGFR3 expression status are noted below the patient identifier. The mean ΔCt (CtTarget - CtGAPDH) is shown to indicate the differences in absolute expression levels between each gene (the lower the ΔCt value the greater the expression level).
*
Patient samples represent diagnostic samples